A PHASE I SAFETY AND PHARMACOKINETIC STUDY OF EVEROLIMUS, AN ORAL MTOR INHIBITOR, IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION ArticlePeveling-Oberhag J., Zeuzem S., Yong W.P., Kunz T., Paquet T., Bouillaud E., Urva S., Anak O., Sellami D., Kobalava Z.EUROPEAN JOURNAL OF CANCER. Vol. 47. 2011.
VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN NONPREGNANT HUMAN ENDOMETRIUM AND ITS GENETIC POLYMORPHISMS: CONTRIBUTION TO RECURRENT PREGNANCY LOSS ArticleSadekova O.N., Nikitina L.A., Rashidov T.N., Demidova E.M., Samokhodskaya L.M.Placenta. Vol. 32. 2011.